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Abstract It is well established that interactions between
tumor cells and the host tissue stroma play a key role in
determining whether and how any given solid malignancy
will develop. In most cases, tumor cells hijack stromal cell
functions for their own beneWt and ultimately dictate the
rules of engagement to the host tissue microenvironment.
However, the contribution of the diVerent stromal cell com-
ponents to tumor growth remains to be clariWed. Because
most solid tumors are accompanied by a local inXammatory
response, it has long been thought that inXammation and
carcinogenesis are related. If formal proof that cancer can
be initiated by inXammation in the absence of exogenous
carcinogens is still lacking, there is abundant evidence that
the inXammatory response can play a central role in modu-
lating tumor growth and progression. This review will dis-
cuss some of the mechanisms whereby inXammation can
both enhance and inhibit tumor growth.
Keywords Carcinogenesis · InXammation · Cytokines · 
Mediators · Tumor-associated macrophages · Lymphocytes
Introduction
It is becoming increasingly apparent that the tumor
microenvironment plays a determining role in cancer
development. Host tissue cells, including Wbroblasts and
other components of the cellular stroma are not passive
bystanders in tumor growth and invasion but are active par-
ticipants in the promotion of neoplastic propagation
throughout the organism (Tlsty and Coussens 2006).
Indeed, tumor growth depends, in large part, on the func-
tional relationship between tumor and stromal cells, includ-
ing, among others, macrophages, mast cells, adipocytes,
and Wbroblasts. Whenever carcinoma cells breach the natu-
ral barrier constituted by the basement membrane, they for
the Wrst time enter into direct physical contact with the host
tissue stroma. The extent of what follows depends in part
on the biological properties of the tumor cells and in part on
the composition of the invaded stroma. However, tumor
cells invariably cause a stromal reaction whose nature and
amplitude vary according to the tumor type and a variety of
individual traits.
A typical stromal reaction to neoplastic cells begins with
the recruitment and activation of mesenchymal stem cells,
endothelial cell precursors, Wbroblasts, dendritic cells and a
variety of leukocyte subsets (Olumi et al. 1999). Along
with the tumor cells themselves, these diVerent cell types
secrete a variety of growth factors, chemokines and
enzymes, that contribute to the ensuing tissue remodelling,
as deWned by the degradation of existing and deposition of
new extracellular matrix (ECM) proteins and proteogly-
cans, and angiogenesis (Fig. 1). Together, these events
resemble those that follow tissue injury, and have led to the
description of cancer by Harold Dvorak as a “wound that
never heals” (Dvorak 1986).
Stromal reaction to tissue injury, whether induced by
trauma or infection, represents a defense mechanism of the
organism that strives to limit the extent of the damage,
eliminate the oVending agent, if one is present, and restore
the integrity of the tissues. Stromal reaction to invading
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injury, it may constitute a defense mechanism to a patho-
logical situation represented by the growth of aberrant cells
that may mimic aspects of tissue injury; a more perverse
interpretation would be that tumor cells harbour a program
to elicit a stromal response that will facilitate tumor pro-
gression and dissemination as part of the tumor cell quest
for survival. The correct interpretation probably lies some-
where in between the two––it is likely that the initial stro-
mal response is indeed a defense mechanism that becomes
subverted by the tumor cells, which can eVectively counter-
act the growth inhibitory eVects of the stromal reaction and
harness its growth promoting eVects for their own beneWt.
Incubation of normal human Wbroblasts with culture
media conditioned by metastatic prostate cancer cell lines
illustrates the importance of the eVect of tumor cell-derived
factors on the host tissue stroma (Kaminski et al. 2006).
Tumor cell-conditioned culture media-stimulated Wbro-
blasts are reported to display a phenotype reminiscent of
carcinoma-associated Wbroblasts (CAFs), secreting kerati-
nocyte growth factor (KGF), tumor necrosis factor-
(TNF), basic Wbroblast growth factor (bFGF), platelet
derived growth factor (PDGF), hepatocyte growth factor
(HGF) and vascular endothelial growth factor (VEGF), that
can in turn stimulate proliferation of both normal and neo-
plastic cells. Conversely, Wbroblast conditioned culture
medium can enhance proliferation and anchorage-independent
growth of some carcinoma cell lines and facilitates migra-
tion of others (Kaminski et al. 2006). CAFs have also been
reported to stimulate transformation and progression of ini-
tiated prostate epithelial cells (Olumi et al. 1999).
Understanding how tumor cells control and beneWt from
host tissue responses could open the way toward designing
therapeutic strategies targeting the molecular mechanisms
that underlie relevant tumor-host interactions. Successful
targeting of such mechanisms could result in severance of
stromal support and functional isolation of tumor cells lead-
ing either to their demise or their sensitization to conven-
tional and new therapies. A key issue, therefore, is to
elucidate the mechanisms involved and to determine which
events to target, bearing in mind that these may vary
according to the tumor type and stage of progression. This
review will focus on the role of the inXammatory response
to tumor growth.
A brief overview of inXammation
Tissue injury, whether physical, chemical or infectious,
triggers a sequence of events that constitute the inXamma-
tory response. InXammation is characterized by coordinated
blood borne delivery to injured tissues of soluble mediators
and cells that can eliminate the agent responsible for the
injury and initiate tissue repair. Mast cells and tissue-resident
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activated in response to injury and behave as orchestrators
of the series of events that follow. Mast cells, which reside
along vessel walls, are readily activated by crosslinking of
cell surface Fc receptors and by C3a and C5a fragments of
the complement, generated by the presence of bacteria and/
or immune complexes. Activated mast cells rapidly release
preformed vasoactive amines, principally histamine, which
determine the early vascular response, characterized by a
transient arteriolar constriction followed by capillary and
venular dilatation and augmented endothelial permeability.
Macrophages are also activated by Fc receptor crosslinking,
C3a and C5a, as well as mediators released by injured cells
and the F-Met-Leu-Phe peptide of bacterial cell walls. Acti-
vated macrophages produce a host of cytokines, chief
among which are interleukin-1 (IL-1), TNF and IL-6. IL-1
and TNF have similar and synergistic eVects on vascular
endothelial cells that include endothelial cell activation and
expression of E- and P-selectin as well as intercellular
adhesion molecule-1 (ICAM-1) on the cell surface. E- and
P-selectin recognize sialylated and fucosylated oligosac-
charides on E-selectin ligand (ESL) and P-selectin glyco-
protein ligand-1 (PSGL-1) expressed on the surface of
neutrophils, monocytes and lymphocyte subsets (Hidalgo
et al. 2007). Interaction between endothelial cell selectins
and their leukocyte ligands is typically of low aYnity yet
suYcient to cause rolling of leukocytes on the endothelial
surface. Close contact between endothelial cells and leuko-
cytes facilitates stimulation by activated endothelial cell
and macrophage-derived chemokines, including interleu-
kin-8 (CXCL8), which recognizes speciWc G-protein cou-
pled receptors (GPCRs) on neutrophils and monocytes.
Triggering by IL-8 induces neutrophil activation, one con-
sequence of which is a conformational change in 2 inte-
grins, principally LFA-1, that allows high aYnity
interaction with ICAM-1 expressed on the surface of acti-
vated endothelial cells. The LFA-1/ICAM-1 interaction
causes leukocyte arrest on the endothelium, a step that pre-
cedes and is required for diapedesis. The arrested leuko-
cytes can then extravasate and migrate toward the site of
tissue injury. Within the tissues, activated neutrophils can
phagocytose and destroy harmful agents such as bacteria,
thereby playing a major role in clearing the etiology of the
injury. Within hours to days, the local chemokine and acti-
vated endothelium adhesion receptor repertoire become
adapted to help recruit other leukocyte subsets. Thus, the
initial wave of neutrophils is followed by the inXux of a
variety of lymphocyte subsets and monocytes that can
diVerentiate locally into macrophages.
InWltrating leukocytes release their own panel of cyto-
kines and chemokines, including IL-1, IL-2, IL-4, IL-5, IL-
10, IL-12, gamma interferon, CCL2, CCL20, CXCL1,
CXCL2, CXCL5 and many others, the combination of
which helps deWne the type of inXammatory inWltrate and
the corresponding immune reaction. They also release a
variety of lipid mediators and growth factors, including
VEGF, PDGF, transforming growth factor  (TGF) that
stimulate angiogenesis and activate Wbroblasts to synthe-
size and secrete ECM components, as well as numerous
proteolytic enzymes, including cathepsins and matrix
metalloproteinases (MMPs) that participate in ECM protein
breakdown. As the inXammation progresses, and the etio-
logic agents are gradually eliminated, the balance shifts
from inXammation-driven tissue remodelling to tissue
repair. A key factor in this transition is the switch in cell-
derived lipid mediators from the pro-inXammatory prosta-
glandins to the anti-inXammatory lipoxins. Lipoxins help
recruit monocytes rather than neutrophils, which diVerenti-
ate into macrophages that remove local debris and coordi-
nate subsequent repair. During the early phase of this
transition, the area undergoing remodeling contains abun-
dant, highly permeable capillaries, Wbroblasts and macro-
phages and is often referred to as granulation tissue.
Granulation tissue is gradually replaced by a provisional
matrix, composed principally of collagen III and Wnally by
collagen I that will constitute the scar tissue whose extent
depends on the severity of the initial injury, its duration, the
regenerative capacity of the host tissue and a variety of as
yet poorly understood individual traits.
If the acute inXammatory response fails to eliminate the
cause of the injury, the inXammatory process may persist
but acquires new features. The neutrophil inWltrate is
replaced by monocytes and macrophages, and depending
on the nature of the pathogen, by lymphocytes. If the eVect
of these cells is still insuYcient to clear the tissue of the
oVending agent, a chronic inXammatory state develops.
Depending on the pathogen and type of host response, the
inXammation may be granulomatous or lymphocytic with
the formation of tertiary lymphoid tissues.
InXammation and cancer
In 1863, R. Virchow recorded the presence of leukocytes in
neoplastic lesions and hypothesized that malignant trans-
formation originates from chronically inXamed tissues
(Balkwill and Mantovani 2001), providing the Wrst concep-
tual framework for linking inXammation and cancer. Clini-
cal and experimental observations of the past two decades
increasingly support the notion that immune cells recruited
to and activated within the tumor microenvironment play a
strong supporting role in tumor progression (Brigati et al.
2002). The release of a myriad of inXammatory mediators
including cytokines, chemokines, growth factors, proteases,
lipids and other molecules, by the combination of tumor
and stromal cells, have been shown to modulate the tumor123
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motility of the cells, by the way of autocrine and paracrine
signalling pathways (Balkwill 2004).
Recruitment of leukocytes by tumors
The inXammatory response to tumor growth may be
induced by at least two non-mutually exclusive mecha-
nisms. Tumor growth and invasion are associated with sig-
niWcant cell death, some of which occurs by apoptosis and
some of which occurs by necrosis. Necrotic cells release
numerous mediators of inXammation, including the high
mobility group box 1 protein (HMGB1) which is a potent
stimulator of macrophages (Chen et al. 2007). Similar to
normal cells dying as a result of trauma or infection, tumor
cells undergoing necrosis may trigger an analogous tissue
response. The second mechanism whereby tumor cells may
induce an inXammatory response is by secreting cytokines
and chemokines that activate resident Wbroblasts, macro-
phages and mast cells and recruit monocytes and lympho-
cytes. A key coordinator of innate immunity and
inXammation that also behaves as an endogenous tumor
promoter in NF-B (Maeda and Omata 2008). In leuko-
cytes, NF-B functions downstream of pathogen or tissue
injury sensors, including the Toll-like receptor (TLR)-MyD88,
and the IL-1 receptor (IL-1R) and TNF receptor (TNFR)
signalling pathways (Naugler and Karin 2008). In tumor
cells, NF-B can be activated as a result of cell autonomous
genetic alterations. Its action in both normal and tumor
cells consists of inducing the expression of inXammatory
cytokines, adhesion receptors, angiogenic factors, inducible
nitric oxide synthase (iNOS) and enzymes implicated in the
synthesis of arachidonic acid metabolites, including cyclo-
oxygenase-2 (COX-2). NF-B is also a major survival fac-
tor by virtue of its ability to induce expression of Bcl2.
Examination of most primary invasive as well as meta-
static tumor biopsies reveals an inXammatory inWltrate that
varies in composition and intensity (Fig. 2). InWltrates may
range from sparse myeloid cells and T cells to dense popu-
lations of neutrophils, monocytes/macrophages, dendritic
cells, natural killer cells or T and B lymphocytes (Brigati
et al. 2002). The functional role of the various leukocyte
components of any tumor inWltrate remains to be fully elu-
cidated, but evidence suggests that it may diVer from that
observed in the context of physiological tissue repair. Thus,
T cell inWltration of the neoplastic microenvironment may
be expected to be beneWcial for cancer patient (Wakabay-
ashi et al. 2003; LeVers et al. 2008), yet it often fails to cor-
relate with good prognosis. Abundance of innate immune
cells, including mast cells and macrophages, often corre-
lates with angiogenesis and poor prognosis (Nonomura
et al. 2007; Taskinen et al. 2008). Current opinion, based
on several lines of experimental evidence, holds that
inXammation can be both cancer stimulatory and cancer
inhibitory, depending on the composition of the inWltrating
cell populations, the context, and stage of tumor develop-
ment. Precise evaluation of the numbers of macrophages
and T cells within cancer nests compared to the stroma
has been suggested as a means to obtain a biomarker for
Fig. 2 Variability of the 
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et al. 2008).
The role of macrophages and lymphocytes in tumor 
growth
Macrophages are often the most abundant immune cell
population in the tumor microenvironment. Recruitment of
monocyte precursors circulating in the blood leads to their
diVerentiation into tumor-associated macrophages (TAM).
The CCL2 chemokine released by tumor cells, may be a
key TAM chemoattractant (Matsushima et al. 1989) along
with other molecules including, VEGF, PDGF, TGF and
macrophage colony stimulating factor (M-CSF) (Coussens
and Werb 2002).
Just as microenvironmental cytokines selectively pro-
mote a Th1 or Th2 immune response, they may also polar-
ize macrophages toward the M1 or M2 phenotype, each
expressing specialized functional properties. Interferon-
(IFN) and microbial molecules induce activation of M1
macrophages, which can support a Th1 immune response,
while IL-4, IL-10 and IL-13 induce M2 macrophage activa-
tion and promote a Th2 response (Mantovani et al. 2004).
The phenotype of TAM resembles that of M2 cells, with
pro-tumor functions that include inhibition of Th1 adaptive
immunity, production of growth and survival factors
including, epidermal growth factor (EGF), IL-6 and
CXCL8, and the secretion of angiogenic factors including,
VEGF, PDGF, TGF, along with a variety of chemokines.
TAM can also induce the degradation and remodelling of
ECM via the expression of MMPs, and suppress Th1 adap-
tive immune responses by the production of immunosup-
pressive mediators (IL-10, PGE2, TGF) and chemokines
capable of recruiting Th2 cells (CCL17, CCL18 and
CCL22) (Mantovani et al. 2002; Allavena et al. 2008b).
Taken together, TAM play an important role in supporting
tumor progression, tissue remodeling, and angiogenesis,
while suppressing Th1 type adaptive immunity (Sica and
Bronte 2007).
Recent evidence suggests that in some tumor models,
TAM are an obligate tumor cell partner during intravasa-
tion and initiation of metastasis (Bunt et al. 2007).
Newly formed vessels not only supply tumor cells with
nutrients, but provide them with a means to disseminate to
other organs. Deletion of colony stimulating factor-1 (CSF-
1) in a mouse model of multistage mammary carcinogene-
sis revealed reduced angiogenic response, diminished
tumor invasion and abrogation of lung metastasis as a result
of deWcient macrophage recruitment into the tumor micro-
environment (Lin et al. 2001). Intravital imaging of murine
mammary carcinoma models provides direct evidence that
macrophages enhance metastasis by stimulating tumor
motility and facilitating tumor cell intra- and extravasation
(WyckoV et al. 2004). Consistent with these observations,
the number of macrophages present in the tumor stroma
correlates with increased microvessel density, cell prolifer-
ation and tumor size in breast cancers and decreased sur-
vival in endometrial cancers (Tsutsui et al. 2005). In other
experiments, depletion of peritoneal macrophages resulted
in slower tumor development from tumor cells injected into
the peritoneal cavity or portal vein (Lin and Pollard 2007).
All of these observations suggest that macrophage inWl-
trates potentiate tumor cell growth and dissemination, at
least in part by promoting angiogenesis. Other leukocytes,
including mast cells and neutrophils that inWltrate the neo-
plastic stroma can contribute to angiogenesis by producing
many of the angiogeneic factors secreted by macrophages
and by releasing proteolytic enzymes that degrade the ECM
and liberate sequestered growth factors (Ribatti et al. 2004).
Lymphocytes may play a dual role in tumor progression.
On the one hand tumor-speciWc cytotoxic T cells have the
capacity the eliminate tumor cells by direct or antibody-
dependent target cell killing. However, recruitment of regu-
latory T cells and secretion of IL-10 and TGF by either the
tumor cells or TAM blunts the immune response and may
neutralize the cytolytic potential of cytotoxic T cells
(Mantovani et al. 2008). Having produced or harnessed an
eVective protection mechanism against immune attack,
tumor cells may draw beneWts from lymphoid cell inWltra-
tion. DiVerent lymphocyte subsets secrete IL-2, IL-3, IL-4,
IL-5, IL-10, IL-12, IL-13 and TGF that can help amplify
the inXammatory response on the one hand and directly
aVect tumor cells on the other.
Consistent with the M2 phenotype of TAM, pre-malig-
nant and malignant tissues are reported to be associated
with enhanced humoral immunity at the expense of Th1
cell and cytoxic T lymphocyte activity, both of which are
suppressed (Agarwal et al. 2006; Johansson et al. 2008). By
enhancing humoral immunity and suppressing cytotoxic T
cell activity, Th2 cell-derived IL4 and IL-10 increase the
risk of neoplastic transformation in tissues aZicted with
chronic inXammatory disease and that harbor initiated neo-
plastic cells (Tan and Coussens 2007).
InXammatory mediators in the tumor 
microenvironment
AmpliWcation of the inXammatory response consists of an
increased inXux of leukocytes into the tumor site that
results in the secretion and continuous activation of media-
tors of inXammation, including cytokines, chemokines,
cell-derived arachidonic acid metabolites, nitric oxide and
reactive oxygen species (ROS), proteolytic enzymes and
plasma-derived coagulation factors and complement. The123
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inXuencing and regulating cell proliferation, migration,
angiogenesis, tissue remodelling, metabolism and genomic
integrity (Hussain and Harris 2007).
Pro-inXammatory cytokines
The cytokine repertoire produced in the initial response to
tissue injury plays a major role in determining the nature of
the cellular inWltrate and the corresponding immune
response. The pro-inXammatory cytokines IL-1 and TNF
are induced by hypoxia, which is a common feature of
tumor but not of healthy tissues under physiological condi-
tions (Koong et al. 2000). Both cytokines stimulate their
own and each other’s production, thereby establishing an
important ampliWcation loop of the local inXammatory
response (Apte and Voronov 2008).
TNF can be detected in malignant and/or stromal cells
in several human carcinomas, lymphomas, and leukaemias,
often in association with IL-1. Although TNF is involved
in the homeostasis of the immune system, inXammation and
host defence, it can also display pro-tumorigenic eVects.
Thus, mice lacking the gene that encodes TNF are resis-
tant to skin carcinogenesis initiated by dimethylbenzanthra-
cene (DMBA) and promoted by phorbolesters,
underscoring the importance of TNF during the early
stages of tumor development (Moore et al. 1999). Consis-
tent with this notion, overexpression of the TNF gene can
also confer a metastatic phenotype on primary tumor cells
(Malik et al. 1990). Several of the known consequences of
TNF production by cancer cells that help explain its role
in cancer progression, have been recently reviewed (Balk-
will 2006).
The IL-1 family includes IL-1, IL-1, IL-1 receptor
antagonist (IL-1Ra), IL-18 and IL-33 (reviewed by Arend
et al. 2008). IL-1, IL-18 and IL-33 are synthesized as pre-
cursors and must be processed by the cysteine protease
caspase-1 to biologically active mature forms that are
released from cells. Depending on the stimulus, caspase-1,
also called IL-1 converting enzyme (ICE), can induce
secretion of pro-inXammatory cytokines or trigger cell
pyroptosis, a caspase-1-dependent cell death pathway (Ting
et al. 2008). Pyroptosis is characterized by loss of plasma
membrane integrity, resulting in the release of pro-inXam-
matory cellular contents into the microenvironment that
induce and maintain the inXammatory process (Fink and
Cookson 2005). Caspase-1 itself requires cleavage by a
multiprotein complex to become active and process IL-1.
The multiprotein complex, called the inXammasome, is
composed of several distinct proteins including the Nod-
like receptor protein Nalp3. The Nalp3 inXammasome is
assembled in response to a variety of signals, including the
presence of asbestos, ROS and monosodium urate, and trig-
gers robust secretion of IL-1 that may lead to a chronic
inXammatory state in the lung (for the case of asbestos),
joints (monosodium urate, gout) or other organs (Petrilli
and Martinon 2007; Dostert et al. 2008).
The IL-1 family induces expression of numerous pro-
inXammatory genes, including COX-2, the inducible NOS,
MMPs and pro-inXammatory cytokines capable of recruit-
ing leukocytes to the tumor site. Endothelial cell prolifera-
tion has been shown to be stimulated by IL-1, as has
expression of integrins and other adhesion receptors, all of
which constitute mechanisms whereby IL-1 family mem-
bers promote the inWltration of inXammatory cells, tumor
invasiveness and angiogenesis (Voronov et al. 2003; Apte
and Voronov 2008). This notion has been corroborated
using IL-1Ra, which binds the IL-1 receptor but has no bio-
logical activity and thereby constitutes a competitive inhib-
itor of IL-1. Delivery of IL-1Ra to the tumor site has been
observed to reduce local inXammation, inhibit cancer pro-
gression and decrease lung metastases in mice at least in
part by counteracting the proangiogenic eVect of IL-1,
(Bar et al. 2004; Lavi et al. 2007). These observations raise
the possibility that IL-1Ra may constitute an attractive
reagent in anticancer therapy, in addition to its already
promising eVects in chronic inXammatory diseases.
Although experimental models provide and essential
vehicle toward elucidating the eVects of any given cytokine
on tumorigenesis and tumor progression, they often provide
an oversimpliWcation of the actual physiological role within
the natural context of the tumor. Cytokines in fact occa-
sionally display dual roles and dose-dependence in the
physiological context of a tumor, rendering true assessment
of their function challenging. For example, in addition to its
central role in inXammation, the proform of IL-1 can have
an oncogenic eVect when overexpressed in mesangial cells
(Stevenson et al. 1997). Similarly, the dual eVect of IL-18
in tumor progression is illustrated by its ability to stimulate
natural killer and T cells which eliminate nascent tumor
cells on the one hand, yet to display pro-carcinogenic func-
tions on the other, that include promotion of VEGF produc-
tion, which itself stimulates IL-18 mRNA synthesis in a
dose-dependent manner. (Kim et al. 2007). IL-18 also
induces MMP-9 expression, and may thereby be a signiW-
cant player in tumor cell migration, invasion and metastasis
(Park et al. 2007).
Reactive oxygen and nitrogen species (ROS and RNS)
ROS are generated by normal physiological processes,
including aerobic metabolism and inXammatory responses.
At physiological concentrations, they participate in the reg-
ulation of a variety of cellular processes ranging from tran-
scription to proliferation. In specialized cells, such as
neutrophils, they can be generated in bursts within deWned123
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ing. In excess (oxidative stress), they can inXict cellular
damage and play an important role in tumorigenesis.
ROS and reactive nitrogen species (RNS) are widely
released in tumor microenvironment by activated immune
cells and can function as chemical eVectors in inXamma-
tion-driven carcinogenesis. ROS and RNS can cause DNA
damage that results in replication errors and genomic insta-
bility, contributing to tumor initiation, and RNS can also
inactivate DNA repair enzymes (Jaiswal et al. 2000; Mar-
nett 2000). Excess of nitric oxide has been shown to induce
expression of a variety of transcription factors associated
with the regulation of tumor growth (AP-1, p53) and to
modulate their activity or stability or those of their inhibi-
tors (NF-B). In addition, RNS can modulate accessibility
of promoters via increased DNA methylation or histone
deacetylation (Kroncke 2003).
Nitric oxide can enhance migration, invasion and metas-
tasis of breast and colon cancer cells by activating the
MAPK pathway (Jadeski et al. 2003). It also increases
VEGF expression in tumor cells, promoting angiogenesis
and tumor progression, and induces posttranslational modi-
Wcation of key regulators of tumor growth and inXamma-
tion, including p53and COX-2 (Fukumura et al. 2006).
Nitric oxide distribution and localization are critical for its
eVect on tumor propagation: its concentration has been
shown to be increased in stromal Wbroblasts and immune
cells in many human tumors, independent of its production
by tumor cells. Host produced nitric oxide has been sug-
gested to have tumoricidal activity and to participate in the
suppression of tumor growth and metastasis in mice (Wei
et al. 2003).
Growth factors
Beyond a critical size of about 400 , that may vary accord-
ing to tumor type, the initial aggregate of tumor cells requires
its own blood supply. This is typically achieved by the induc-
tion of angiogenesis as a result of synthesis and secretion of
angiogenic factors that include VEGF, bFGF, TGF, angio-
poietin-2 and several others (Karamysheva 2008). Whereas
some tumor cells are capable of secreting their own angio-
genic factors, others rely on host cell-driven angiogenesis. In
ovarian and breast cancer, leukocytes, and particularly TAM
secrete abundant VEGF as well as a variety of proteolytic
enzymes, including urokinase-type plasminogen activator
(uPA) and MMP-9 that participate in angiogenesis.
Arachidonic acid metabolites
The two mains classes of arachidonic acid derivatives are
prostaglandins and leukotrienes, both of which participate
actively in the regulation of inXammation.
Prostaglandins are cyclooxygenase-dependent deriva-
tives of arachidonic acid that display proinXammatory
activity ranging from the regulation of vascular volume and
permeability to platelet aggregation. A strong argument that
inXammation supports tumor growth and progression stems
from the observation that non-steroidal anti-inXammatory
drugs that block COX-2 have a potent inhibitory eVect on
tumor growth (Gupta and Dubois 2001; Rostom et al.
2007). COX-2 is an inducible isoenzyme that acts as an
immediate early gene expressed in response to cytokines,
growth factors, and other stimuli to produce prostaglandins.
Because COX-2 is usually overexpressed in colon cancer,
COX-2 inhibitors are currently being tested as a therapeutic
option in colon cancer management. However, despite
promising results in colon cancer prevention and a tangible
reduction in the incidence of colon adenomas, nonsteroidal
anti-inXammatory drugs and COX-2 inhibitors can incur
severe cardiovascular and gastrointestinal side eVects that
hinder their routine use for cancer treatment (Bertagnolli
et al. 2006; Rostom et al. 2007).
Proteolytic enzymes
Enzymes released by leukocytes also contribute to the con-
tinuous tissue remodelling that characterizes cancer. Mac-
rophages, as well as neutrophils and lymphocytes express
and secrete a variety of MMPs that together have the poten-
tial to hydrolyse all known ECM proteins (for review, see
Van Kempen et al. 2006). Continued release and activation
of MMPs results in degradation of ECM glycoproteins and
proteoglycans with several major consequences. First, deg-
radation of macromolecules such as collagens reduces the
physical barriers that tumor cells have to overcome as they
migrate toward lymphatic and blood vessels. Second, some
of the ECM protein degradation products, display bioactiv-
ity of their own. A prominent example is the release of
cryptic fragments of laminin as a result of MMP-mediated
cleavage of laminin-5 2 chains that mimic EGF receptor
(EGFR) ligands and induce cell migration and invasive
potential in EGFR expressing cells (Schenk et al. 2003).
Third, degradation of proteoglycans results in the release
and activation of a multitude of ECM-sequestered growth
factors, augmenting their bioavailability to tumor cells.
Proteolytic activation of growth factor precursors can also
occur at the cell surface. Thus, leukocyte-derived MMP-7
cleaves and activates cell surface pro-heparin-binding EGF
(HB-EGF) into its bioactive form, which enhances tumor
cell migration and survival (Li et al. 2006). Together with
cathepsins, MMP-7 can also cleave E-cadherin, facilitating
tumor cell disaggregation and enhancing motility (Lee et al.
2007). Thus, leukocyte-derived proteolytic enzymes have
the ability to alter tumor cell adhesion while promoting
migration, survival and growth, and it comes as no surprise123
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sue often correlates with poor prognosis (Egeblad and
Werb 2002). One important aspect of leukocyte-derived
MMPs is that they may provide the tissue remodelling force
that certain malignant cells may not have, since not all
tumor types display high expression levels of MMPs and
other proteolytic enzymes. By recruiting and harnessing the
inXammatory response, weakly invasive tumor cells may
acquire the means to disseminate.
Systemic mediators
InXammation enhances coagulation, both by augmenting
platelet aggregation and by inducing regulators of the clot-
ting cascade, including plasmin and uPA. Circulating tumor
cells can express cell surface receptors decorated by oligo-
saccharides that constitute selectin ligands (Borsig et al.
2001). In activated platelets, preformed P-selectin seques-
tered within -granules is translocated to the cell surface
and mediates platelet binding to tumor cells expressing the
corresponding ligands. Similarly, leukocytes expressing L-
selectin can bind to circulating tumor cells leading to the
formation of large aggregates that may create microemboli
in the capillaries and facilitate arrest within the vasculature
of distant organs. Such aggregates may also serve to protect
tumor cells from shear stress in the circulation and aggres-
sion by natural killer cells and cytotoxic lymphocytes (Bar-
thel et al. 2007).
Plasmin and uPA participate in ECM and Wbrin degrada-
tion that contribute to tissue remodelling and facilitate
tumor cell invasion.
Similar to inXammation induced by bacteria or trauma,
complement activation constitutes an integral part of can-
cer-associated inXammation. Sustained complement activa-
tion results in continuous stimulation of macrophages, mast
cells and neutrophils. Complement fragments, particularly
C5a are also among the most potent chemotactic molecules
for a variety of leukocytes and ensure continued recruit-
ment of leukocytes to sites of tumor growth.
Preparation of metastatic niches
Following injection of B16F1 melanoma cells into mice,
only 2% are observed to form micrometastatic foci, and
less than 0.2% activate angiogenesis and develop a second-
ary tumor (Luzzi et al. 1998). At Wrst glance, these
“selected” cells capable of forming metastases seems to be
rare. However, proliferation of these cells at secondary sites
may not be a reXection of their intrinsic properties, but
rather that of the preparation of the local tissue or “soil” to
provide them with a permissive microenvironment. Recent
evidence suggests that hematopoietic progenitor cells Wrst
home to pre-metastatic sites and promote recruitment of
tumor cells from the blood, favoring their subsequent out-
growth by the robust expression of VEGF receptor (Kaplan
et al. 2005). Consistent with this notion, the release of
VEGF, TGF and TNF from the primary tumor site was
shown to promote the expression of S100 proteins, which
act as chemoattractants for tumor cells in premetastatic
lung sites (Hiratsuka et al. 2006). Because TAM and mast
cells are potent producers of TNF, TGF and VEGF, the
inXammatory inWltrates at primary tumor sites may be
implicated in the formation of the premetastatic niche by
releasing these pro-inXammatory factors into the circula-
tion. If the chemoattracted tumor cells encounter hemato-
poietic progenitor cells at such premetastatic sites, the
angiogenic switch necessary for subsequent metastatic cell
survival and outgrowth could be facilitated (for review, see
DeNardo et al. 2008).
Chronic inXammation as a predisposition to cancer
Substantial evidence supports the notion that inXammation
participates in providing the conditions that lead to trans-
formation. Colon cancer, hepatocellular carcinoma, esopha-
geal and gastric cancer, Epstein-Barr virus-associated
Burkitt’s lymphoma and human papilloma virus (HPV)-
associated cervical cancer are all salient examples of
tumors arising in a context of chronic inXammation.
Common inducers of chronic inXammatory responses
include viral and bacterial infections as well as prolonged
exposure to irradiation or environmental carcinogens.
These infections and chronic inXammation contribute to at
least 25% of all cancer cases. The multifactorial network of
inXammatory mediators, including ROS, imposes a stress
that can induce genetic and epigenetic changes as well as
relevant post-translational modiWcations of macromole-
cules. In the medium to long term, sustained inXammatory
stress can cause alterations in critical signalling pathways
responsible for maintaining cellular homeostasis, leading to
growth dysregulation and cancer (Hussain and Harris
2007).
The association between Crohn’s disease, and particu-
larly ulcerative colitis, and colon cancer is well established
(Eaden et al. 2000). Similarly, there is a tight association
between hepatitis B (HBV) and C (HCV) viruses and
hepatocellular carcinoma (Matsuzaki et al. 2007). In both
cases of hepatitis, the mechanism whereby viral genes
induce transformation is unclear. The HBx gene of the
HBV genome has been implicated in transformation,
presumably by aVecting both p53 and Rb (Kwun and
Jang 2004). However, hepatocellular carcinoma can also
arise in the context of alcoholic liver cirrhosis that is unre-
lated to viral infection. It is believed that the chronic123
Histochem Cell Biol (2008) 130:1079–1090 1087inXammation induced by HBV and HCV plays a role in
stimulating hepatocyte proliferation and augments the like-
lihood of developing transforming mutations. Cirrhosis rep-
resents a more obvious terrain for cancer development,
where chronic inXammation leads to aberrant liver regener-
ation that presents an increased risk for oncogenic muta-
tions to occur.
Helicobacter pylori, a gram-negative bacterium associ-
ated with gastric ulcer, is an established carcinogen in gas-
tric cancer development, the second most frequent
malignancy in the world. Chronic inXammation that accom-
panies ulcers is believed to be the condition that causes
DNA damage leading to malignant transformation of gas-
tric epithelial cells (Lochhead and El-Omar 2007; McNa-
mara and El-Omar 2008).
Recent work has shed light onto the molecular path-
ways that link gastrointestinal tumorigenesis and inXam-
mation. Mutation of the gene encoding the APC protein,
frequently associated with gastrointestinal malignancies,
induces chronic activation of the Wnt/-catenin signalling
pathway, which plays a central role in modulating the bal-
ance between stemness and diVerentiation in several cell
types (Fodde and Brabletz 2007). Under pressure of H.
pylori, macrophages are continuously recruited by the
sustained presence of pro-inXammatory cytokines. Hence,
the abundantly available macrophage-derived TNF
engages its receptor on gastric epithelial cells leading to
nuclear accumulation of -catenin, which promotes
growth dysregulation initiated by the APC mutation
(Oguma et al. 2008).
HPV and EBV-associated malignancies are typical
examples of tumors arising the in the context of viral infec-
tions. Although HPV and EBV-mediated transformation is
supported by well established mechanistic events within the
infected cells themselves, the resulting inXammatory
response and suppression of adaptive immunity are both
believed to play a major role in the subsequent emergence
of malignant tumors. In a mouse model of cancer induce by
HPV, antibodies have been shown to be deposited in the
stroma. By binding to ECM molecules, these antibodies
trigger an inXammatory response than favors tumor pro-
gression (Psyrri and DiMaio 2008).
Although inXammation alone has not yet been shown
to be a suYcient condition for cancer development, recent
work further strengthens the link between these two
events. Using Nalp3¡/¡ mice, investigators have shown
diminished recruitment of inXammatory cells to the lungs
in response to asbestos inhalation, with lower correspond-
ing cytokine production (Dostert et al. 2008). These
observations place the Nalp3 inXammasome at the center
of asbestos-induced chronic lung inXammation that is
well known to promote transformation and malignant
tumor development.
Anti-tumor inXammation
Crosstalk between innate and adaptive immune responses is
mediated by complex interactions between the various cel-
lular players, and it seems conceptually reasonable that the
vast array of soluble factors produced within the tumor
microenvironment can lead to dysregulation of the immune
system, which often favors tumor growth. During acute
inXammatory reactions, the innate immune system activates
and regulates the adaptive immunity. However, in the case
of chronic tissue inXammation, it is often the opposite sce-
nario that is observed, where excessive activation of the
innate immune response, mediated by a dysregulated adap-
tive immune system, culminates in tissue damage (De Vis-
ser and Coussens 2005). Thus, innate and adaptive
immunity both have the potential to promote or delay tumor
onset and progression, depending on the balance between
the pro- and anti-tumor mediators synthesized by the vari-
ous immune cells.
Despite the accumulating clinical and experimental evi-
dence that inXammation has tumor-stimulating activity,
there are several examples where the opposite may hold
true. Some chronic inXammatory states, a salient example
being psoriasis, are not associated with an increased risk of
developing cancer. In addition, the presence of inXamma-
tory cells can be an indicator of favorable prognosis in
some tumor types (for example the presence of eosinophils
in colon cancer and TAM in pancreatic carcinoma). These
observations suggest that at least in some situations,
inXammatory cells may be able to eliminate tumor cells
just as they can destroy normal cell counterparts. Experi-
mental evidence supports this notion based on the observa-
tion that appropriately activated macrophages can kill
tumor cells and elicit a tumor-inhibitory inXammatory
response (Allavena et al. 2008a). A key player in deter-
mining the type of macrophage response to tumor cells
appears to be NF-B (Hayden et al. 2006). NF-B may
therefore constitute a therapeutic target that could poten-
tially be re-programmed to direct macrophages to exert
their anti-tumor properties.
Lessons from psoriasis may be important in understand-
ing what regulates the balance between pro- and anti-tumor
inXammatory responses. Psoriasis is a Th1 cell-mediated
disorder characterized by massive inWltration of neutrophils
and monocytes in the skin (NickoloV et al. 2005). The
monocytes can diVerentiate into macrophages with an M1
phenotype, which display anti-tumor activity. Hence, the
inXammatory response associated with psoriasis does not
facilitate tumor development because of the overwhelming
presence of macrophages capable of eliminating nascent
tumor cells. It should be borne in mind that potential dual-
ity of the inXammatory response to cancer can be regulated
by the tissue type, as suggested by a skin tumor model123
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invasive epidermal carcinoma (Dajee et al. 2003).
The precise mechanisms that help trigger an anti-cancer
inXammatory response remain to be elucidated. However, it
would seem that being able to steer inXammation toward a
Th1/M1 versus Th2/M2 type response may provide a pow-
erful means to control tumor growth. How to achieve this
will obviously require a better understanding of the pro-and
anti-tumor microenvironments and the molecular mecha-
nisms that guide their constitution.
Perspectives
Despite an abundance of new insight into the association
between inXammation and cancer development and progres-
sion, numerous important questions remain. It has still not
been clearly established whether chronic inXammation can in
and of itself, in the absence of an exogenous carcinogen, lead
to transformation. Although there are indications that inXam-
mation can cause cancer, formal proof is still lacking.
Whereas most malignant tumors are associated with
inXammatory inWltrates, it would seem that the composition
of the inWltrates varies from tumor to tumor and even
according to the stage of tumor development. What regu-
lates the type of inXammatory response to any given tumor
type and are there functionally relevant and therapeutically
targetable common denominators among inXammatory
responses to various tumor types? Answers to these ques-
tions will be crucial.
There is strong evidence that Th1/M1 responses may
protect from tumor development whereas Th2/M2
responses support tumor development and progression.
What are the microenvironmental conditions that determine
which type of response occurs, and how might we be able
to re-direct Th2/M2 to Th2/M1 type responses?
Clearly, we need a much better understanding of cancer-
associated inXammation in order to target it in patients with
cancer. However, the abundance of recent discoveries pre-
dicts that cancer-related inXammation research is poised for
exciting times.
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